ELF3
ELF3 (ETS-related transcription factor Elf-3) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Colorectal cancer and Biliary tract cancer.
Overview
Transcriptional activator that binds and transactivates ETS sequences containing the consensus nucleotide core sequence GGA[AT]. Acts synergistically with POU2F3 to transactivate the SPRR2A promoter and with RUNX1 to transactivate the ANGPT1 promoter. Also transactivates collagenase, CCL20, CLND7, FLG, KRT8, NOS2, PTGS2, SPRR2B, TGFBR2 and TGM3 promoters.
Open Targets scores its association with cancer at 0.61 (direct and indirect evidence; datatypes literature 0.98, animal model 0.27, genetic association 0.06, somatic mutation 0.78). IntOGen calls it a driver in 9 cohorts (4 activating, 4 loss-of-function), covering Bladder Urothelial Carcinoma, Cholangiocarcinoma, Colorectal Adenocarcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · ELF3 (ETS-related transcription factor Elf-3) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Colorectal cancer and Biliary tract cancer.
- 1 · What it is
ELF3 (ETS-related transcription factor Elf-3) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Colorectal cancer and Biliary tract cancer.
- 2 · What goes wrong in cancer
Transcriptional activator that binds and transactivates ETS sequences containing the consensus nucleotide core sequence GGA[AT].
- 3 · How drugs use it
No product in this corpus aims at ELF3 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:3318 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P78545 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000163435 (association with cancer (MONDO_0004992) 0.61; per-cancer scores at or above 0.5: urinary bladder cancer 0.56 (GraphQL API, CC0)); IntOGen ELF3 (driver in 9 cohorts (Act 4, LoF 4); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Transcriptional activator that binds and transactivates ETS sequences containing the consensus nucleotide core sequence GGA[AT]. Acts synergistically with POU2F3 to transactivate the SPRR2A promoter and with RUNX1 to transactivate the ANGPT1 promoter. Also transactivates collagenase, CCL20, CLND7, FLG, KRT8, NOS2, PTGS2, SPRR2B, TGFBR2 and TGM3 promoters. Represses KRT4 promoter activity. Involved in mediating vascular inflammation. May play an important role in epithelial cell differentiation and tumorigenesis. Location: Cytoplasm; Nucleus (UniProt). Locus 1q32.1 (HGNC).
- Bladder & urothelial cancer: Open Targets association 0.56 with urinary bladder cancer (MONDO_0001187); IntOGen driver in 6 cohorts (BLCA)
- Colorectal cancer: IntOGen driver in 1 cohort (COADREAD)
- Biliary tract cancer: IntOGen driver in 2 cohorts (CHOL)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 4 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 4 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"ELF3" OR ABSTRACT:"ELF3" OR TITLE:"E74 like ETS transcription factor 3" OR ABSTRACT:"E74 like ETS transcription factor 3" OR TITLE:"ETS-related transcription factor Elf-3" OR ABSTRACT:"ETS-related transcription factor Elf-3" OR TITLE:"EPR-1" OR ABSTRACT:"EPR-1" OR TITLE:"ESE-1" OR ABSTRACT:"ESE-1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ELF3, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetZNF429
Shares Biliary tract cancer (cholangiocarcinoma), Bladder & urothelial cancer, IntOGen, Open Targets Platform.
- TargetN4BP2
Shares Biliary tract cancer (cholangiocarcinoma), Bladder & urothelial cancer, IntOGen.
- TargetRBM10
Shares Biliary tract cancer (cholangiocarcinoma), Bladder & urothelial cancer, IntOGen, Open Targets Platform.
- TargetGPC5
Shares Biliary tract cancer (cholangiocarcinoma), IntOGen, Open Targets Platform.
- TrialA Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Shares Biliary tract cancer (cholangiocarcinoma), Bladder & urothelial cancer, Colorectal cancer.
- TargetPRKD1
Shares Biliary tract cancer (cholangiocarcinoma), IntOGen, Open Targets Platform, Colorectal cancer.
- TargetANK1
Shares Biliary tract cancer (cholangiocarcinoma), IntOGen, Colorectal cancer.
- TargetCLTC
Shares Biliary tract cancer (cholangiocarcinoma), Bladder & urothelial cancer, IntOGen, Open Targets Platform.